Fertility benefits company Progyny (NASDAQ: PGNY) will be reporting earnings this Thursday after market close. Here’s what to look for.
Progyny beat analysts’ revenue expectations last quarter, reporting revenues of $313.3 million, up 9.3% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ revenue estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Is Progyny a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Progyny’s revenue to grow 3.3% year on year, slowing from the 10.6% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Progyny has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Progyny’s peers in the health insurance providers segment, some have already reported their Q4 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.2%, beating analysts’ expectations by 2%, and Cigna reported revenues up 10.4%, topping estimates by 3.8%. CVS Health traded up 1.6% following the results while Cigna was also up 7.5%.
Read our full analysis of CVS Health’s results here and Cigna’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Progyny is down 16.3% during the same time and is heading into earnings with an average analyst price target of $30.91 (compared to the current share price of $20.90).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
